Methionine sulfoxide reductase: A novel schizophrenia candidate gene

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 150, Issue 2, 2009, Pages 219-225

  Walss Bass, Consuelo ^a,h   Soto Bernardini, Maria Clara ^b   Johnson Pais, Teresa ^c   Leach, Robin J ^a,c   Ontiveros, Alfonso ^d   Nicolini, Humberto ^e   Mendoza, Ricardo ^f   Jerez, Alvaro ^g   Dassori, Albana ^a   Chavarria Siles, Ivan ^a   Escamilla, Michael A ^a   Raventos, Henriette ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g International Center for Affective Illnesses   (Guatemala)

^h NONE   (United States)

Author keywords

Central valley of costa rica; Deletion variant; Linkage disequilibrium; Protection; Under transmission

Indexed keywords

MESSENGER RNA; METHIONINE SULFOXIDE REDUCTASE;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MARKER GENE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ALLELES; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; OXIDOREDUCTASES; SCHIZOPHRENIA;

EID: 61449152907     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30791     Document Type: Article

References (35)

1. Anderson MA, Gusella JF. 1984. Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines. In Vitro 20(11):856-858.
2. Badner JA, Gershon ES. 2002. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7(4):405-411.
3. Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G, Thornquist M, Ullrich G, McGrath J, Kasch L, et al. 1998. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 20(1):70-73.
4. Brzustowicz LM, Honer WG, Chow EW, Little D, Hogan J, Hodgkinson K, Bassett AS. 1999. Linkage of familial schizophrenia to chromosome 13q32. Am J Hum Genet 65(4):1096-1103.
5. Cabreiro F, Picot CR, Friguet B, Petropoulos I. 2006. Methionine sulfoxide reductases: Relevance to aging and protection against oxidative stress. Ann N Y Acad Sci 1067:37-44.
6. De Luca A, Sacchetta P, Di Ilio C, Favaloro B. 2006. Identification and analysis of the promoter region of the human methionine sulphoxide reductase A gene. Biochem J 393(Pt1): 321-329.
7. Escamilla MA, Spesny M, Reus VI, Gallegos A, Meza L, Molina J, Sandkuijl LA, Fournier E, Leon PE, Smith LB, et al. 1996. Use of linkage disequilibrium approaches to map genes for bipolar disorder in the Costa Rican population. Am J Med Genet 67(3):244-253.
8. Escamilla MA, Ontiveros A, Nicolini H, Raventos H, Mendoza R, Medina R, Munoz R, Levinson D, Peralta JM, Dassori A, et al. 2007.
9. A genome-wide scan for schizophrenia and psychosis susceptibility loci in families of Mexican and Central American ancestry. Am J Med Genet Part B 144B(2):193-199.
10. Gabbita SP, Aksenov MY, Lovell MA, Markesbery WR. 1999. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem 73(4):1660-1666.
11. Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sherrington R, Mankoo BS, Read T, Murphy P, Blaveri E, McQuillin A, et al. 2001. Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21 and provides support for linkage to schizophrenia, on chromosomes 11q23. 3-24and 20q12.1-11.23. Am J Hum Genet 68(3):661-673.
12. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, et al. 2007. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proc Natl Acad Sci USA 104(42):16621-16626.
13. Horvath S, Xu X, Laird NM. 2001. The family based association test method: Strategies for studying general genotype-phenotype associations. Eur J Hum Genet 9(4):301-306.
14. Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, Meyer J, Zambuto CT, Schmitt K, Matise TC, et al. 1998. NIMH genetics initiative millenium schizophrenia consortium: Linkage analysis of African-American pedigrees. Am J Med Genet 81(4):282-289.
15. Kendler KS, MacLean CJ, O'Neill FA, Burke J, Murphy B, Duke F, Shinkwin R, Easter SM, Webb BT, Zhang J, et al. 1996. Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry 153(12):1534-1540.
16. Kim HY, Gladyshev VN. 2006. Alternative first exon splicing regulates subcellular distribution of methionine sulfoxide reductases. BMC Mol Biol 7:11.
17. Kim HY, Gladyshev VN. 2007. Methionine sulfoxide reductases: Selenoprotein forms and roles in antioxidant protein repair in mammals. Biochem J 407(3):321-329.
18. Kuschel L, Hansel A, Schonherr R, Weissbach H, Brot N, Hoshi T, Heinemann SH. 1999. Molecular cloning and functional expression of a human peptide methionine sulfoxide reductase (hMsrA). FEBS Lett 456(1):17-21.
19. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, et al. 2003. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 73(1):34-48.
20. Mahadik SP, Mukherjee S. 1996. Free radical pathology and antioxidant defense in schizophrenia: A review. Schizophr Res 19(1):1-17.
21. Mahadik SP, Scheffer RE. 1996. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent FattyAcids 55(1-2):45-54.
22. Moskovitz J, Jenkins NA, Gilbert DJ, Copeland NG, Jursky F, Weissbach H, Brot N. 1996. Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Proc Natl Acad Sci USA 93(8):3205-3208.
23. Moskovitz J, Bar-Noy S, Williams WM, Requena J, Berlett BS, Stadtman ER. 2001. Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc Natl Acad Sci USA 98(23):12920-12925.
24. Ophoff RA, Escamilla MA, Service SK, Spesny M, Meshi DB, Poon W, Molina J, Fournier E, Gallegos A, Mathews C, et al. 2002. Genomewide linkage disequilibrium mapping of severe bipolar disorder in a population isolate. Am J Hum Genet 71(3):565-574.
25. Owen MJ, Craddock N, O'Donovan MC. 2005. Schizophrenia: Genes at last? Trends Genet 21(9):518-525.
26. Peers B, Voz ML, Monget P, Mathy-Hartert M, Berwaer M, Belayew A, Martial JA. 1990. Regulatory elements controlling pituitary-specific expression of the human prolactin gene. Mol Cell Biol 10(9):4690-4700.
27. Peers B, Monget P, Nalda MA, Voz ML, Berwaer M, Belayew A, Martial JA. 1991. Transcriptional induction of the human prolactin gene by cAMP requires two cis-acting elements and at least the pituitary-specific factor Pit-1. J Biol Chem 266(27):18127-18134.
28. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, et al. 2004. Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9(7):684-697, 643.
29. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S. 2007. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 6(1):141-149.
30. Pulver AE, Lasseter VK, Kasch L, Wolyniec P, Nestadt G, Blouin JL, Kimberland M, Babb R, Vourlis S, Chen H, et al. 1995. Schizophrenia: A genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. Am J Med Genet 60(3):252-260.
31. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. 2003. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121(2):109-122.
32. Ruan H, Tang XD, Chen ML, Joiner ML, Sun G, Brot N, Weissbach H, Heinemann SH, Iverson L, Wu CF., et al. 2002. High-quality life extension by the enzyme peptide methionine sulfoxide reductase. Proc Natl Acad Sci USA 99(5):2748-2753.
33. Walss-Bass C, Montero AP, Armas R, Dassori A, Contreras SA, Liu W, Medina R, Levinson D, Pereira M, Atmella I, et al. 2006. Linkage disequilibrium analyses in the Costa Rican population suggests discrete gene loci for schizophrenia at 8p23.1 and 8q13.3. Psychiatr Genet 16(4):159-168.
34. Wassef R, Haenold R, Hansel A, Brot N, Heinemann SH, Hoshi T, 2007. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms. J Neurosci 2747 12808-12816.
35. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR. 2007. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry 68(5):754-760.